---
title: "石药创新制药股份有限公司 (300765.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/300765.SZ.md"
symbol: "300765.SZ"
name: "石药创新制药股份有限公司"
industry: "制药"
---

# 石药创新制药股份有限公司 (300765.SZ)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 沪深市场 |
| Website | [www.xnwpharma.net](https://www.xnwpharma.net) |

## Company Profile

公司始建于 1989 年，2006 年改为股份制企业，2019 年在深交所挂牌上市。公司产品通过了国家新版 GMP 质量认证、美国 FDA 认证、欧盟 EDQM 认证、日本 PMDA、英国 BRC 认证等多项质量体系认证，获得了海内外客户的广泛认可，产品远销欧、美、日、澳、东南亚等国家和地区。公司的主营业务为生物制药和功能食品及原料的研发、生产和销售。主要产品为恩朗苏拜单抗注射液、注射用奥马珠单抗、咖啡因、阿卡波糖、果维康维生素 C 含片等。公司获得的荣誉有河北省企业技术中心、河北省科学技术成果奖、2018 年河北省专利奖优秀奖等。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: C (0.58)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 74 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.69% |  |
| Net Profit YoY | -157.11% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 12.79 |  |
| Dividend Ratio | 0.06% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 47.17B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 2.09B |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -2.92% | D |
| Profit Margin | -5.23% | D |
| Gross Margin | 42.84% | B |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.69% | C |
| Net Profit YoY | -157.11% | E |
| Total Assets YoY | 8.61% | B |
| Net Assets YoY | -12.29% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -1910.45% | E |
| OCF YoY | 0.69% | C |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.35 | D |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 32.94% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 石药创新制药股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-2.92%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-5.23%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "42.84%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.69%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-157.11%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.61%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-12.29%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-1910.45%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "0.69%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.35",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "32.94%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 艾力斯 (SH.688578) | A | A | B | A | B | A |
| 02 | 兴齐眼药 (SZ.300573) | A | A | A | B | B | A |
| 03 | 恒瑞医药 (SH.600276) | A | B | C | A | B | B |
| 04 | 云南白药 (SZ.000538) | B | C | B | B | C | B |
| 05 | 信立泰 (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -430.14 | 221/222 | 1077.37 | 914.76 | 101.28 |
| PB | 12.79 | 215/222 | 19.71 | 15.65 | 13.17 |
| PS (TTM) | 22.52 | 211/222 | 37.55 | 29.36 | 23.59 |
| Dividend Yield | 0.06% | 158/222 | 0.07% | 0.05% | 0.04% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-31T16:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 50% |
| Overweight | 1 | 25% |
| Hold | 1 | 25% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 33.58 |
| Highest Target | 61.40 |
| Lowest Target | 52.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/300765.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/300765.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/300765.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.